(Q35818518)

10 August 2017

1 reference

title

Global strategies to prevent bacterial pneumonia in adults with HIV disease (English)

1 reference

10 August 2017

0 references

1 reference

1

Daniel R Feikin

1 reference

10 August 2017

3

Anne Schuchat

1 reference

10 August 2017

Charles Feldman

2

1 reference

10 August 2017

Edward N Janoff

series ordinal

4

1 reference

10 August 2017

publication date

1 July 2004

1 reference

Lancet Infectious Diseases

10 August 2017

published in

1 reference

10 August 2017

volume

4

1 reference

10 August 2017

issue

7

1 reference

10 August 2017

page(s)

445-455

1 reference

Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Bacterial pneumonia in patients with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Bacterial pneumonia in hospitalized patients with HIV infection: the Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Community-acquired pneumonia: impact of immune status

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Surveillance for Legionnaires' disease. Risk factors for morbidity and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Bacteremia in HIV-positive and AIDS patients: incidence, species distribution, risk-factors, outcome, and influence of long-term prophylactic antibiotic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

A prospective study of community-acquired bloodstream infections among febrile adults admitted to Mulago Hospital in Kampala, Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Bacterial pneumonia in HIV-infected patients: a prospective study of 68 episodes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Bacteraemia and mortality among adult medical admissions in Malawi--predominance of non-typhi salmonellae and Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

A hospital-based prevalence survey of bloodstream infections in febrile patients in Malawi: implications for diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Pneumococcal bacteremia with pneumonia. Mortality in acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Invasive pneumococcal disease in the immunocompromised host

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Incidence and risk factors for pneumonia in HIV infected and non-infected drug users

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Respiratory tract infection in HIV-1-infected adults in Nairobi, Kenya: evaluation of risk factors and the world health organization treatment algorithm

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complex

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Risk factors in HIV-1-infected patients developing repetitive bacterial infections: toxicological, clinical, specific antibody class responses, opsonophagocytosis and Fc(gamma) RIIa polymorphism characteristics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. Terry Beirn Community Programs for Clinical Research on AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Severe pneumococcal sepsis and meningitis in human immunodeficiency virus-infected adults with sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

The impact of bacteraemia on HIV infection. Nine years experience in a large Italian university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Pneumonia and Hong Kong influenza: a prospective study of the 1968-1969 epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Adverse Reactions to Trimethoprim-Sulfamethoxazole in Patients with the Acquired Immunodeficiency Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Community-acquired bacteremia in HIV-positive patients: protective benefit of co-trimoxazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Impact of trimethoprim-sulfamethoxazole prophylaxis on etiology and susceptibilities of pathogens causing human immunodeficiency virus-associated bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Multistate evaluation of invasive pneumococcal diseases in adults with human immunodeficiency virus infection: serotype and antimicrobial resistance patterns in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Influence of CD4+ status on the invasiveness of pneumococcal pneumonia in HIV patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Co-trimoxazole in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Adherence to guidelines for the prevention of HIV-related respiratory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Antibody Responses After Influenza and Pneumococcal Immunization in HIV-Infected Homosexual Men

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Response to pneumococcal vaccine among asymptomatic heterosexual partners of persons with AIDS and intravenous drug users infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Equal IgG antibody response to pneumococcal vaccination in all stages of human immunodeficiency virus disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Deficient antipneumococcal polysaccharide responses in HIV-seropositive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Pneumonia in HIV-infected patients: a case-control survey of factors involved in risk and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

No evidence that vaccination with a polysaccharide pneumococcal vaccine protects drug users against all-cause pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Assessments of Plasma HIV RNA and CD4 Cell Counts after Combined Pneumovax® and Tetanus Toxoid Vaccination: No Detectable Increase in HIV Replication 6 Weeks after Immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Viral load response to a pneumococcal conjugate vaccine, polysaccharide vaccine or placebo among HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

The effects of immunization in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Immune activation and virologic response to immunization in recent HIV type 1 seroconverters

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Haemophilus influenzae pneumonia in young adults with AIDS, ARC, or risk of AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Epidemiological aspects of major opportunistic infections of the respiratory tract in persons with AIDS: Europe, 1993-2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Impact of HAART on causes of death of persons with late-stage AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Pulmonary Infiltrates in HIV-Infected Patients in the Highly Active Antiretroviral Therapy Era in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

HIV-associated bacteremia: how it has changed in the highly active antiretroviral therapy (HAART) era.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

The changing pattern of bronchoscopy in an HIV-infected population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

High-dose intravenous immunoglobulins in HIV-1-infected adults with AIDS-related complex and Walter-Reed 5.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Efficacy of intravenous immunoglobulins in patients with advanced HIV-1 infection. A randomized clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Possible role of granulocyte-macrophage colony stimulating factor (GM-CSF) on the rapid progression of AIDS-related Kaposi's sarcoma lesions in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Pneumococcal bacteremia in adults in Soweto, South Africa, during the course of a decade

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901060-6

7 January 2021

10.1016/S1473-3099(04)01060-6

Identifiers

DOI

1 reference

10 August 2017

1 reference